Level of interleukin-35 in patients with idiopathic membranous nephropathy and its predictive value for remission time.
Level of interleukin-35 in patients with idiopathic membranous nephropathy and its predictive value for remission time.
复制标题
DOI：
10.3389/fimmu.2022.926368
复制
发表时间：
2022
影响因子：
7.3
通讯作者：
中科院分区：
文献类型：
--
作者：
白细胞介素-35（IL-35）是白细胞介素-12家族成员之一，在免疫应答中起着重要的调节作用。IL-35与特发性膜性肾病（IMN）的关系尚不清楚，本研究旨在阐明IL-35与IMN疾病活动性及缓解的关系。本研究为单中心、回顾性研究，所有患者均经肾活检或aPLA 2 R滴度确诊为IMN，并给予麻黄附子合肾浊汤治疗。以临床完全缓解或部分缓解（CR+PR）为终点进行随访。检测血清IL-35水平，分析其与IMN缓解的关系。采用流式细胞术检测IMN患者外周血中调节性T细胞（Treg）和产生IL-35的诱导性T细胞（iTR 35）的水平。共随访76例IMN患者（年龄51.95 ± 13.29），随访时间为18（12，24）个月。所有患者治疗后血清IL-35水平均升高，但缓解组升高程度明显高于未缓解组（117.6% vs83.7%，P<0.01）。缓解组基线IL-35水平高于未缓解组（174.87 vs.151.87pg/ml，P=0.016）。考克斯回归分析显示，基线IL-35水平是IMN缓解的独立危险因素（HR 1.081，95%CI 1.048-1.116，P<0.001）。基线IL-35低于下四分位数（≤145.49 pg/ml）的患者的平均缓解时间是基线IL-35高于上四分位数（> 203.05 pg/ml）的患者的2倍（12个月vs. 24个月，P<0.01）。基线IL-35可以预测aPLA 2 R阳性（AUC=0.673）或阴性（AUC=0.745）的IMN患者的缓解时间。18例IMN患者IL-35水平与iTR 35相关性较高，与Treg无相关性（r=0.613，P<0.05）。IMN患者IL-35水平随治疗进展呈上升趋势，基线IL-35水平可预测IMN患者（包括aPLA 2 R阴性患者）的缓解时间。IL-35的水平与iTR 35细胞的数量有关。
As a member of interleukin-12 family, interleukin-35 (IL-35) plays an important regulatory role in immune response. The relationship between IL-35 and idiopathic membranous nephropathy (IMN) is still unclear, and the purpose of this study is to clarify the relationship between IL-35 and disease activity and remission of IMN. This study was a single-center, retrospective study in which all patients were diagnosed with IMN by renal biopsy or aPLA2R titer and treated with Mahuang Fuzi and Shenzhuo Decoction (MFSD). A follow-up was conducted with the endpoint of clinical complete or partial remission (CR+PR). Levels of serum IL-35 were measured and its relationship with IMN remission were analyzed. The regulatory T cell (Treg) and inducible IL-35 producing Tregs (iTR35) in peripheral blood of IMN patients were detected by flow cytometry. A total of 76 IMN patients (age 51.95 ± 13.29) were followed-up for 18 (12, 24) months. The level of serum IL-35 in all patients increased after treatment, but the degree of increase in remission group was significantly higher than that in no remission (NR) group (117.6% vs 83.7%, P<0.01). The baseline IL-35 level in remission group was higher than that in NR group (174.87 vs.151.87 pg/ml, P=0.016). Cox regression analysis showed that baseline IL-35 level was a independent risk factor for IMN remission (HR 1.081, 95%CI 1.048-1.116, P<0.001). Patients with baseline IL-35 lower than the lower quartile (≤145.49 pg/ml) had an average remission time twice as long as those with baseline IL-35 higher than the upper quartile (> 203.05 pg/ml) (12mon vs. 24mon, P<0.01). The baseline IL-35 can predict the remission time of IMN patients with either aPLA2R positive (AUC=0.673) or negative (AUC=0.745). Analysis of 18 patients with IMN showed that IL-35 level had a higher correlation with iTR35, but not Treg (r=0.613, P<0.05). The level of IL-35 in patients with IMN showed an increasing trend with the progress of treatment, and the baseline IL-35 could predict the remission time of IMN patients, including those patients with negative aPLA2R. The level of IL-35 is related to the number of iTR35 cells.
影响因子：
7.3
作者：
Mohd Shukri ND;Farah Izati A;Wan Ghazali WS;Che Hussin CM;Wong KK
通讯作者：
Wong KK